Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nortriptyline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 0.94 |
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 0.94 |
| ▸ | HRH1 | P35367 | 7/20 | 0.94 |
| ▸ | LMNA | P02545 | 6/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.94 |
| ▸ | HTR2B | P41595 | 6/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.94 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.94 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.94 |
| ▸ | DRD2 | P14416 | 5/20 | 0.94 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.94 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.94 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.94 |
| ▸ | HTR2A | P28223 | 5/20 | 0.94 |
| ▸ | HTR2C | P28335 | 5/20 | 0.94 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.94 |
| ▸ | DRD3 | P35462 | 5/20 | 0.94 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nortriptyline SCHEMBL1286980 | 0.97 | SLC6A2 (1.00) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL29362430 | 0.97 | SLC6A2 (1.00) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL34527 | 0.97 | SLC6A2 (1.00) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL41329 | 0.95 | CYP3A4 (1.00) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL7158809 | 0.95 | SLC6A2 (0.97) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL29751879 | 0.95 | CYP3A4 (1.00) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL7092935 | 0.94 | LMNA (0.94) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Amitriptyline SCHEMBL3897883 | 0.87 | SLC6A2 (0.81) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| SCHEMBL22147029 | 0.86 | LMNA (0.78) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| SCHEMBL21859431 | 0.86 | LMNA (0.78) | SLC6A2HRH1LMNACYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011194-A | Amitriptyline antibody and kit | 中南大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| CN-117147669-A | Mass spectrum method and kit for rapidly and simultaneously detecting multi-component compounds in body fluid and preparation method thereof | 武汉大学 | 2023-12-01 | — | — | CN | disclosed |
| US-8629135-B2 | Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-01-14 | — | — | US | disclosed |
| US-20110201598-A1 | Pharmaceutical Compositions Comprising RET Inhibitors and Methods for the Treatment of Cancer | GUJRAL, TARANJIT S. | 2011-08-18 | — | — | US | disclosed |
| US-20100222311-A1 | SOLID FORMULATIONS OF CRYSTALLINE COMPOUNDS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201598-A1 | Pharmaceutical Compositions Comprising RET Inhibitors and Methods for the Treatment of Cancer | RET, THRB, SKP1 | SLC6A2 3547/4885SLC6A4 3730/4885HRH1 106/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | SLC6A2 804/4885SLC6A4 2649/4885HRH1 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.